Q1 consolidated revenue was $3.9M, reflecting initial U.S. sales of Lymphir at Citius Oncology (CTOR). Cash and cash equivalents totaled $7.7M as of December 31, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTXR: